Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
Baize N, Monnet I, Greillier L, Geier M, Lena H, Janicot H, Vergnenegre A, Crequit J, Lamy R, Auliac JB, Letreut J, Le Caer H, Gervais R, Dansin E, Madroszyk A, Renault PA, Le Garff G, Falchero L, Berard H, Schott R, Saulnier P, Chouaid C; Groupe Français de Pneumo-Cancérologie 01–13 investigators. Baize N, et al. Among authors: auliac jb. Lancet Oncol. 2020 Sep;21(9):1224-1233. doi: 10.1016/S1470-2045(20)30461-7. Lancet Oncol. 2020. PMID: 32888454 Clinical Trial.
Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
Vergnenegre A, Corre R, Berard H, Paillotin D, Dujon C, Robinet G, Crequit J, Bota S, Thomas P, Chouaid C; 0506 GFPC Team. Vergnenegre A, et al. J Thorac Oncol. 2011 Jan;6(1):161-8. doi: 10.1097/JTO.0b013e318200f4c1. J Thorac Oncol. 2011. PMID: 21150465 Free article. Clinical Trial.
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
Chouaid C, Le Caer H, Locher C, Dujon C, Thomas P, Auliac JB, Monnet I, Vergnenegre A; GFPC 0504 Team. Chouaid C, et al. Among authors: auliac jb. BMC Cancer. 2012 Jul 20;12:301. doi: 10.1186/1471-2407-12-301. BMC Cancer. 2012. PMID: 22817667 Free PMC article. Clinical Trial.
Assessment of palliative care for advanced non-small-cell lung cancer in France: a prospective observational multicenter study (GFPC 0804 study).
Vergnenègre A, Hominal S, Tchalla AE, Bérard H, Monnet I, Fraboulet G, Baize N, Audigier-Valette C, Robinet G, Oliviero G, Le Caer H, Thomas P, Gérinière L, Mastroianni B, Chouaïd C; GFPC 0804 team. Vergnenègre A, et al. Lung Cancer. 2013 Nov;82(2):353-7. doi: 10.1016/j.lungcan.2013.07.014. Epub 2013 Aug 6. Lung Cancer. 2013. PMID: 23932456
Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).
Chouaid C, Dujon C, Do P, Monnet I, Madroszyk A, Le Caer H, Auliac JB, Berard H, Thomas P, Lena H, Robinet G, Baize N, Bizieux-Thaminy A, Fraboulet G, Locher C, Le Treut J, Hominal S, Vergnenegre A. Chouaid C, et al. Among authors: auliac jb. Lung Cancer. 2014 Nov;86(2):170-3. doi: 10.1016/j.lungcan.2014.08.016. Epub 2014 Aug 29. Lung Cancer. 2014. PMID: 25214431
Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501.
Gervais R, Le Caer H, Monnet I, Falchero L, Baize N, Olivero G, Thomas P, Berard H, Auliac JB, Chouaid C; Groupe Français de Pneumo-Cancérologie 0501 Team. Gervais R, et al. Among authors: auliac jb. Clin Lung Cancer. 2015 Mar;16(2):100-5. doi: 10.1016/j.cllc.2014.10.002. Epub 2014 Oct 29. Clin Lung Cancer. 2015. PMID: 25467927 Clinical Trial.
Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting.
Sassier M, Dugué AE, Clarisse B, Lesueur P, Avrillon V, Bizieux-Thaminy A, Auliac JB, Kaluzinski L, Tillon J, Robinet G, Le Caer H, Monnet I, Madroszyk A, Boza G, Falchero L, Fournel P, Egenod T, Toffart AC, Leiber N, Do P, Gervais R. Sassier M, et al. Among authors: auliac jb. Lung Cancer. 2015 Aug;89(2):161-6. doi: 10.1016/j.lungcan.2015.05.005. Epub 2015 May 15. Lung Cancer. 2015. PMID: 26037036
Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.
Fournel P, Vergnenégre A, Robinet G, Léna H, Gervais R, Le Caer H, Souquet PJ, Chavaillon JM, Bozonnat MC, Daurès JP, Chouaid C, Martel-Lafay I; GFPC and IFCT Team. Fournel P, et al. Eur J Cancer. 2016 Jan;52:181-7. doi: 10.1016/j.ejca.2015.10.072. Epub 2015 Dec 12. Eur J Cancer. 2016. PMID: 26689864 Clinical Trial.
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.
Corre R, Greillier L, Le Caër H, Audigier-Valette C, Baize N, Bérard H, Falchero L, Monnet I, Dansin E, Vergnenègre A, Marcq M, Decroisette C, Auliac JB, Bota S, Lamy R, Massuti B, Dujon C, Pérol M, Daurès JP, Descourt R, Léna H, Plassot C, Chouaïd C. Corre R, et al. Among authors: auliac jb. J Clin Oncol. 2016 May 1;34(13):1476-83. doi: 10.1200/JCO.2015.63.5839. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884557 Clinical Trial.
63 results